<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Diabetes Mellitus — Overview</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
  line-height: 1.6;
  background-color: #f9f9f9;
  color: #333;
}
h1, h2, h3 {
  color: #0066cc;
}
table {
  width: 100%;
  border-collapse: collapse;
  margin: 15px 0;
}
table, th, td {
  border: 1px solid #ccc;
}
th, td {
  padding: 8px;
  text-align: center;
}
th {
  background-color: #e6f0ff;
}
.section {
  margin-bottom: 30px;
}
</style>
</head>
<body>

<h1>🩺 Diabetes Mellitus — Overview</h1>

<div class="section">
<h2>📌 Definition</h2>
<p>
Diabetes Mellitus (DM) is a group of chronic metabolic diseases characterized by hyperglycemia.
<ul>
<li><b>Type 1 DM (T1DM):</b> Autoimmune destruction of β-cells → absolute insulin deficiency.</li>
<li><b>Type 2 DM (T2DM):</b> Insulin resistance + relative insulin deficiency, associated with obesity & lifestyle.</li>
</ul>
</p>
</div>

<div class="section">
<h2>🔷 Comparison of T1DM and T2DM</h2>
<table>
<tr>
<th>Feature</th><th>Type 1 DM</th><th>Type 2 DM</th>
</tr>
<tr>
<td>Genetics / HLA</td><td>HLA-DR3/DR4+, weak familial</td><td>No HLA, strong familial</td>
</tr>
<tr>
<td>Pathogenesis</td><td>Autoimmune, absolute insulin deficiency</td><td>Insulin resistance + β-cell dysfunction</td>
</tr>
<tr>
<td>Obesity</td><td>❌</td><td>✅</td>
</tr>
<tr>
<td>Onset</td><td>Children/adolescents</td><td>Adults >40</td>
</tr>
<tr>
<td>C-Peptide</td><td>Low/Absent</td><td>High early, low late</td>
</tr>
<tr>
<td>Classic Symptoms</td><td>Common</td><td>Sometimes</td>
</tr>
<tr>
<td>Histology</td><td>Leukocyte infiltrates</td><td>Amyloid deposits</td>
</tr>
<tr>
<td>Treatment</td><td>Insulin</td><td>Lifestyle + oral meds ± insulin</td>
</tr>
</table>
</div>

<div class="section">
<h2>📊 Diagnosis</h2>
<ul>
<li>Random glucose ≥200 mg/dL + symptoms</li>
<li>Fasting glucose ≥126 mg/dL</li>
<li>HbA1c ≥6.5%</li>
<li>OGTT 2h ≥200 mg/dL</li>
<li>Prediabetes: FPG 100-125, HbA1c 5.7–6.4%</li>
</ul>
</div>

<div class="section">
<h2>🔷 Complications</h2>
<ul>
<li>Acute: DKA, HHS, severe hypoglycemia</li>
<li>Chronic Microvascular: nephropathy, retinopathy, neuropathy</li>
<li>Chronic Macrovascular: CAD, stroke, PAD</li>
</ul>
</div>

<div class="section">
<h2>🩺 Management</h2>
<h3>Goals</h3>
<ul>
<li>HbA1c &lt;7% (individualized)</li>
<li>FPG 80-130 mg/dL, postprandial &lt;180 mg/dL</li>
</ul>
<h3>T1DM</h3>
<ul>
<li>Insulin therapy: 0.5 u/kg/day start</li>
<li>Consider insulin pump</li>
</ul>
<h3>T2DM</h3>
<ul>
<li>1st line: Metformin</li>
<li>Add SGLT2i, GLP-1 RA, SU, TZD, or insulin if needed</li>
</ul>
<h3>Lifestyle</h3>
<ul>
<li>Smoking cessation</li>
<li>Weight loss ≥5%</li>
<li>Healthy diet, regular exercise</li>
</ul>
</div>

<div class="section">
<h2>🩷 Follow-Up</h2>
<ul>
<li>Screen annually for microvascular & macrovascular complications</li>
<li>HbA1c every 3–6 months</li>
<li>Lipid profile, albuminuria, eye & foot exams annually</li>
</ul>
</div>

<div class="section">
<h2>👶 Children</h2>
<ul>
<li>T1DM: Insulin pump or multiple injections</li>
<li>T2DM (≥10 years): Metformin ± insulin ± GLP-1 RA</li>
</ul>
</div>

<p style="text-align:center;">© Based on <i>AMBOSS & ADA guidelines</i></p>

</body>
</html>
